Addressing continued growth in global flu vaccine demand and deficiencies in current facilities, this new building is designed to serve the North American market and provide redundant production capabilities within the global supply chain. Integral to the project’s planning are provisions for expansions to double and triple production. The facility incorporates all elements of egg-based vaccine production, including:
- Upstream egg inoculation, harvesting and egg handling (receiving and waste treatment).
- Downstream processing involving discrete, segregated production suites for bulk vaccine development.
- Wash/Sterilization, weight/dispense, and buffer preparation in support of operations.
- Warehouse and staging for staging and materials flows supporting production.
